Irina Kline

705 total citations
13 papers, 539 citations indexed

About

Irina Kline is a scholar working on Genetics, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Irina Kline has authored 13 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in Irina Kline's work include Diabetes Treatment and Management (5 papers), Glioma Diagnosis and Treatment (3 papers) and Pancreatic function and diabetes (3 papers). Irina Kline is often cited by papers focused on Diabetes Treatment and Management (5 papers), Glioma Diagnosis and Treatment (3 papers) and Pancreatic function and diabetes (3 papers). Irina Kline collaborates with scholars based in United States, Canada and France. Irina Kline's co-authors include Keith Usiskin, Gary Meininger, Matthew R. Weir, Albert Fung, Cristiana Mayer, Ujjwala Vijapurkar, Robert Edwards, John Xie, Courtney D. DiNardo and Amir T. Fathi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Neuro-Oncology.

In The Last Decade

Irina Kline

12 papers receiving 525 citations

Peers

Irina Kline

EDM

SURGE

HEMAT

NEPHR

Minako Takeda Japan

Mario Maldonado United States

Sébastian Lechner France

Osman Özdoğan Türkiye

Feng-Ying Lei China

Cynthia L. Gaboury United States

Atsunori Kuwabara Japan

Hisaki Shimada Japan

Olga V. Sakharova United States

John Xu United States

Minako Takeda Japan

Irina Kline

234 ×0.7

EDM

177 ×0.7

192 ×1.1

SURGE

186 ×1.6

HEMAT

71 ×1.1

NEPHR

Citations per year, relative to Irina Kline Irina Kline (= 1×) peers Minako Takeda

Countries citing papers authored by Irina Kline

Since Specialization

Citations

This map shows the geographic impact of Irina Kline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irina Kline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irina Kline more than expected).

Fields of papers citing papers by Irina Kline

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irina Kline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irina Kline. The network helps show where Irina Kline may publish in the future.

Co-authorship network of co-authors of Irina Kline

This figure shows the co-authorship network connecting the top 25 collaborators of Irina Kline. A scholar is included among the top collaborators of Irina Kline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irina Kline. Irina Kline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Schreck, Karisa C., Macarena I. de la Fuente, Irina Kline, et al.. (2025). FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.. Journal of Clinical Oncology. 43(16_suppl).

Schreck, Karisa C., Macarena I. de la Fuente, Irina Kline, et al.. (2025). Abstract CT247: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers. Cancer Research. 85(8_Supplement_2). CT247–CT247. 1 indexed citations

Fuente, Macarena de la, Nicholas Butowski, Jennie Taylor, et al.. (2024). TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST). Neuro-Oncology. 26(Supplement_4). 0–0. 1 indexed citations

Fuente, Macarena de la, Nicholas Butowski, Jennie Taylor, et al.. (2023). CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST). Neuro-Oncology. 25(Supplement_5). v95–v95. 1 indexed citations

Fuente, Macarena I. de la, Jordi Rodón, Rona Yaeger, et al.. (2023). Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.. Journal of Clinical Oncology. 41(16_suppl). 3006–3006. 13 indexed citations

Fathi, Amir T., Courtney D. DiNardo, Irina Kline, et al.. (2018). Alterations in serum bilirubin during enasidenib treatment in patients with or without UGT1A1 mutations.. Journal of Clinical Oncology. 36(15_suppl). e19003–e19003. 3 indexed citations

Fathi, Amir T., Courtney D. DiNardo, Irina Kline, et al.. (2018). Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2. JAMA Oncology. 4(8). 1106–1106. 127 indexed citations

Fathi, Amir T., Courtney D. DiNardo, Irina Kline, et al.. (2017). Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2).. Journal of Clinical Oncology. 35(15_suppl). 7015–7015. 11 indexed citations

Gilbert, Richard E., Matthew R. Weir, Paola Fioretto, et al.. (2016). Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes. 40(3). 247–257. 12 indexed citations

10.

Usiskin, Keith, Irina Kline, Albert Fung, Cristiana Mayer, & Gary Meininger. (2014). Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results. Postgraduate Medicine. 126(3). 16–34. 82 indexed citations

11.

Yamout, Hala, Vlado Perkovic, Melanie J. Davies, et al.. (2014). Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology. 40(1). 64–74. 91 indexed citations

12.

Weir, Matthew R., Irina Kline, John Xie, Robert Edwards, & Keith Usiskin. (2014). Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Current Medical Research and Opinion. 30(9). 1759–1768. 96 indexed citations

13.

Weir, Matthew R., Andrzej Januszewicz, Richard E. Gilbert, et al.. (2014). Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Hypertension. 16(12). 875–882. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact